ARCUS BIOSCIENCES INC
ARCUS BIOSCIENCES INC
Aktie · US03969F1093 · RCUS (XNYS)
Übersicht Finanzkennzahlen
9,24 USD
-8,28 % -0,83 USD
NYSE (XNYS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 20:00

Aktuelle Kurse von ARCUS BIOSCIENCES INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNYS: NYSE
NYSE
RCUS
USD
13.06.2025 20:00
9,24 USD
9,35 USD
-1,18 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -7,32 % 8,20 % -1,07 % -42,54 % -45,55 % -66,79 %

Firmenprofil zu ARCUS BIOSCIENCES INC Aktie

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Unternehmensdaten

Name ARCUS BIOSCIENCES INC
Firma Arcus Biosciences, Inc.
Symbol RCUS
Website https://www.arcusbio.com
Heimatbörse XNYS NYSE
ISIN US03969F1093
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Terry J. Rosen Ph.D.
Marktkapitalisierung 829 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,6 T
Adresse 3928 Point Eden Way, 94545 Hayward
IPO Datum 2018-03-15

Ticker Symbole

Name Symbol
NYSE RCUS

Weitere Aktien

Investoren die ARCUS BIOSCIENCES INC die halten, haben auch folgende Aktien im Depot:
ADAMAS PHARMACEUTICALS INC
ADAMAS PHARMACEUTICALS INC Aktie
AMGEN INC
AMGEN INC Aktie
ANSYS INC
ANSYS INC Aktie
AUTODESK INC
AUTODESK INC Aktie
BARING EURO.SE.TR.DIS. EO
BARING EURO.SE.TR.DIS. EO Fonds
BBVA 22/25 FLR MTN
BBVA 22/25 FLR MTN Anleihe
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
EXTENDED STAY AMERICA INC- PAIRED SHARES
EXTENDED STAY AMERICA INC- PAIRED SHARES Aktie
INCYTE CORP
INCYTE CORP Aktie
INTEL CORP
INTEL CORP Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
MONDELEZ INTERNATIONAL INC - CLASS A
MONDELEZ INTERNATIONAL INC - CLASS A Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025